Get the Stockscreener App
0.742
5.36%
-0.042
Nautilus Biotechnology Inc stock is traded at $0.742, with a volume of 138.94K.
It is down -5.36% in the last 24 hours and down -0.01% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.784
Open:
$0.7605
24h Volume:
138.94K
Relative Volume:
0.83
Market Cap:
$93.60M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-1.325
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
-9.95%
1M Performance:
-0.01%
6M Performance:
-69.08%
1Y Performance:
-71.89%
1-Day Range:
$0.7313
$0.7978
1-Week Range:
$0.7313
$0.8541
52-Week Range:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.742 | 109.23M | 0 | -70.78M | -61.27M | -0.56 |
|
ONC
Beigene Ltd Adr
|
242.20 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.77 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.39 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.98 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
20,256 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Cubist Systematic Strategies LLC - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Nautilus Biotechnology And 2 Other Penny Stocks With Promising Potential - Yahoo Finance
Insiders continue to buy Nautilus Biotechnology, Inc. (NASDAQ:NAUT) and now own 31% shares - simplywall.st
Nautilus Biotechnology chief scientist buys $9,885 in common stock By Investing.com - Investing.com Nigeria
Hsbc Holdings PLC Has $92,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Barclays PLC Buys 19,030 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology chief scientist buys $9,885 in common stock - Investing.com
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Barchart.com
Renaissance Technologies LLC Acquires 95,521 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
JPMorgan Chase & Co. Raises Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Update - Defense World
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Reports Q1 2025 Financial Results - TipRanks
Nautilus Biotechnology targets late 2026 platform launch amid proteoform assay advancements - MSN
Nautilus Biotech’s Earnings Call Highlights Progress and Promise - TipRanks
Nautilus Biotechnology Reports First Quarter 2025 Financial Results - GlobeNewswire
Earnings call transcript: Nautilus Biotechnology Q1 2025 surprises with EPS beat - Investing.com
Nautilus Biotechnology (NAUT) Anticipates Tau Proteoform Assay L - GuruFocus
Nautilus Biotechnology Posts Qtrly Loss Per Share $0.13 - marketscreener.com
Nautilus Biotechnology (NAUT) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday - Defense World
Nautilus Biotechnology Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Increases By 20.5% - Defense World
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 - The Manila Times
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - MarketScreener
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence By Investing.com - Investing.com South Africa
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence - Investing.com India
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating By Investing.com - Investing.com South Africa
Nautilus Biotechnology Reports 2024 Financial Results - TipRanks
Seattle's Nautilus Biotechnology lays off 16% of its staff - The Business Journals
Nautilus Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Nautilus Q4 2024 highlights platform delay - Investing.com
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Nautilus Cuts 16% of Workforce as Biotech Platform Launch Slips to 2026What's Next? - StockTitan
Nautilus Biotechnology Announces Board Changes for 2025 - TipRanks
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):